Ulrich Laufs is Chief of Cardiology and Interventional Cardiologist at Leipzig University Hospital, as well as Professor of Cardiology at Leipzig University, Germany. After completing his training at the Universities of Bochum and Hamburg, he was resident at the University of Cologne and spent 2 years as post-doctoral researcher at the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, USA. Since that time, Professor Laufs has published multiple experimental and clinical studies on the regulation of cardiovascular function by lipoproteins and lipid-modifying medications. Subsequently, he also undertook fellowships at the Universities of Cologne and the Saarland. Before moving to Leipzig in 2017, he was Professor for Clinical and Experimental Medicine and Vice-chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland in Homburg, Germany.

Professor Laufs heads a research group focused on cellular and molecular mechanisms, and clinical studies of cardiovascular prevention with a special interest in lipid disorders. His group has > 500 publications listed medline that have been cited >363,000 times (H-index 89).

Laufs serves as elected member of the board of the German Society of Cardiology, spokesperson of the D•A•CH-Gesellschaft Herz-Kreislauf-Prävention, member of the federal drug commissions of the German Physicians and German Pharmacists and in several editorial boards of cardiovascular journals. Professor Laufs has received numerous honours, including a first place in the Young Investigator Award of the American College of Cardiology, the Population Sciences Award of the European Society of Cardiology, the Paul Martini Award, and the Albert Fraenkel Award of the German Cardiac Society. He is proud member of the EAS for more than a decade participating in multiple EAS activities including consensus papers, commitees, educational activities and serving as co-chair of the German FH-registry (CaReHigh) and in the progam comitee of the 2023 EAS scientific conference.

Contributions

LCN 2025 Guidelines Update Webinar - LithuaniaLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN 2025 Guidelines Update Webinar - KazakhstanLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN 2025 Guidelines Update Webinar – EgyptWebinars on-demandLCN WebinarsLipid Clinic NetworkLCN 2025 Guidelines Update Webinar - LuxembourgWebinars on-demandLCN WebinarsLipid Clinic NetworkOverweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.Epidemiology of FHPublicationPaediatric Lipid Working GroupEAS/ESC Guidelines: Combination therapies - guideline updates and clinical caseWebinars on-demand2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasPublicationGuidelineVery high cardiovascular patients risk profiles across the ASCVD continuumCME Session: Intensive and Early Ldl-C Treatment: for Whom?The essential role of sex and gender in atherosclerosis research: A statement from the Editorial Board of Atherosclerosis and Executive Committee of the European Atherosclerosis SocietyCommentariesPublicationPatients with high and very high CV risk: which are treatment options?LCN WebinarsLipid Clinic NetworkControversy: Are we ready to treat inflammation for ASCVD prevention?92nd EAS Congress 2024Controversy: Are we ready to treat inflammation for ASCVD prevention?Panel Discussion: From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACS91st EAS Congress 2023From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACSLipid management in ACS patients in 2023: a failure or a success?91st EAS Congress 2023From combination therapies to discharge strategies. Practical approaches to meet LDL-C goals in ACSRebuttals: Is there a role for diet and nutrition in LDL lowering?91st EAS Congress 2023Is there a role for diet and nutrition in LDL lowering?Contra - Diet and nutrition is not helpful for LDL-C91st EAS Congress 2023Is there a role for diet and nutrition in LDL lowering?A deep dive into CLEAR OUTCOMES and its implicationsWebinars on-demandDebate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaWhat is new in secondary prevention?90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaLCN Workshop on Clinical Lipidology - GermanyWebinars on-demand(DyslipidemiaReviewReviewLipidologyTreatmentPrimary HyperlipidemiaHypolipidemic drugs)A tale of two trials89th EAS Congress 2021(TriglycerideTreatmentLC Omega 3 fatty acidsCVOTHypolipidemic drugs)Ongoing studiesIntro to Clinical LipidologyCurrent available therapies - PCSK9 inhibitionIntro to Clinical LipidologyGuidelines - ACS & very highrisk patientsAn Introduction to Clinical LipidologyWhen do we need add on therapies to statin?88th EAS Congress 2020(Anti PCSK9ReviewReviewReviewGuidelinesCholesterolTreatmentEzetimibeStatinesHypolipidemic drugs)Reality check - Can we get to goals in guidelines?86th EAS Congress 2018